TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33291741

Group type: EXPERIMENTAL
Intervention: Trabectedin treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Genotyping for pharmacokinetic genes (CYP450 and ABC drug transporters)
Number of subjects: 63
Study: 33291807

Group type: EXPERIMENTAL
Intervention: BoNT-A injections at baseline and visit 2 (3-6 months later)
Number of subjects: 204
Study: 33292000

Group type: EXPERIMENTAL
Intervention: AACVPR protocol
Number of subjects: 76
Study: 33292050

Group type: EXPERIMENTAL
Intervention: Integrated model (IM) approach to oral health interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily brushing/flossing
Number of subjects: 0
Study: 33292183

Group type: EXPERIMENTAL
Intervention: Music-based sessions (7 sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Therapeutic education sessions (7 sessions)
Number of subjects: 80
Study: 33292297

Group type: EXPERIMENTAL
Intervention: Personalized unrestricted-calorie diet for 6 weeks (compliant subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Personalized unrestricted-calorie diet for 6 weeks (non-compliant subjects)
Number of subjects: 30
Study: 33292400

Group type: EXPERIMENTAL
Intervention: Intervention group (semi-structured dialog and information leaflet, postcard reminder)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Intervention group (physicians)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (physicians)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Overall comparison of vaccination rates
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 357
Study: 33292514

Group type: EXPERIMENTAL
Intervention: Enhanced recovery program plus goal-directed hemodynamic therapy (ERP + GDHT)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Enhanced recovery program (ERP)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Pre-ERP (historical control)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 623
Study: 33292530

Group type: EXPERIMENTAL
Intervention: Somatropin (growth hormone) at a mean dose of 0.03 mg/kg/d (SD, 0.01 mg/kg/d)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Somatropin (growth hormone)
Number of subjects: 129
Study: 33292545

Group type: EXPERIMENTAL
Intervention: Preoperative accelerated radiotherapy combined with neoadjuvant and adjuvant chemotherapy (6 cycles of doxorubicin 60 mg/m2)
Number of subjects: 20
Study: 33292582

Group type: EXPERIMENTAL
Intervention: Meropenem or piperacillin-tazobactam (specific dosages and duration not provided)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Group 3 (specific intervention not detailed)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Group 1 (specific intervention not detailed)
Number of subjects: 55
Study: 33292598

Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet (KD) total meal replacement (TMR) program, 10g CH/day, 1600 kcal/day for 6 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet (KD) total meal replacement (TMR) program
Number of subjects: 8
Study: 33292612

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 2 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atorvastatin (in vitro on MCF-7 cells)
Number of subjects: 50
Study: 33292651

Group type: EXPERIMENTAL
Intervention: Cell phone-based hearing screening process and telemedicine specialty referral pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard primary care referral pathway
Number of subjects: 0
Study: 33292659

Group type: EXPERIMENTAL
Intervention: MHH intervention (menstrual cup or reusable pads, analgesia, and MHH education)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: MHH intervention (reusable pads)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: MHH intervention (menstrual cups)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: MHH intervention
Number of subjects: 1732
Study: 33292671

Group type: EXPERIMENTAL
Intervention: Active phototherapy (8 sessions over 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33292676

Group type: EXPERIMENTAL
Intervention: 16-week aerobic and resistance exercise intervention
Number of subjects: 100
Study: 33292683

Group type: EXPERIMENTAL
Intervention: Health system intervention to improve kidney disease care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes
Number of subjects: 0
Study: 33292695

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) treatment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline OCT-A area
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline FA area
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Month 6 FA area
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Correlation between OCT-A and FA area
Number of subjects: 21
Study: 33292788

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser (SML)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study: 33292797

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Both IFX and GLM
Number of subjects: 810
Study: 33292822

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 50
Study: 33292826

Group type: EXPERIMENTAL
Intervention: Parent-administered pediatric tuina
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parent-child interaction group (progressive muscle relaxation exercise)
Number of subjects: 60
Study: 33292848

Group type: EXPERIMENTAL
Intervention: Phone check-ins to collect data about implementation activities
Number of subjects: 19
Study: 33292854

Group type: EXPERIMENTAL
Intervention: HEAL-ABC intervention with behaviour change theory and supportive telephone calls every 2 weeks for 3 months, then monthly for 6 months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care with access to public domain resources
Number of subjects: 72
Study: 33293291

Group type: COMPARATOR
Intervention: Living in the least deprived areas
Number of subjects: 9176

Group type: EXPERIMENTAL
Intervention: Ever been homeless
Number of subjects: 9176

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 9176

Group type: EXPERIMENTAL
Intervention: Substance misuse
Number of subjects: 9176
Study: 33293311

Group type: EXPERIMENTAL
Intervention: Incidence of new-onset type 3c diabetes mellitus during follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life analyses (SF-36, Gastrointestinal Quality of Life Index)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montreal cognitive assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ system physiological performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiomics predictors of AP severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of premature cellular senescence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiparameter MRI scan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulse-wave analysis
Number of subjects: 0
Study: 33293313

Group type: EXPERIMENTAL
Intervention: Moderate or severe pain trajectories
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Severe pain trajectory
Number of subjects: 305

Group type: COMPARATOR
Intervention: Low final pain trajectories
Number of subjects: 305
Study: 33293316

Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor blockers (ARBs)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Continuing ARBs
Number of subjects: 497

Group type: COMPARATOR
Intervention: ARB-exposed patients
Number of subjects: 497
Study: 33293388

Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial ischaemia (MSIMI)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial blood flow (MBF) change
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Adenosine vasodilator stress-induced MBF change
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reactive Hyperemia Index
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Peripheral arterial tonometry or digital vasomotor response
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Blood and psychometric tests
Number of subjects: 126
Study: 33293392

Group type: EXPERIMENTAL
Intervention: Depression (PROMIS score ≥55)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: PROMIS Physical Function
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: EuroQoL five dimensions (EQ-5D)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Modified Rankin Score
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported quality of life
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Foreign-born status
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 450
Study: 33294203

Group type: EXPERIMENTAL
Intervention: Ropinirole 0.5 mg daily and Gabapentin 100 mg daily (combined treatment)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Double dummy placebo control (neither ropinirole nor gabapentin)
Number of subjects: 72
Study: 33294303

Group type: EXPERIMENTAL
Intervention: Prostate health dietary combination formulation (one daily capsule for 60 days)
Number of subjects: 30
Study: 33294812

Group type: EXPERIMENTAL
Intervention: MI-Opioid Taper
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 104
Study: 33294862

Group type: EXPERIMENTAL
Intervention: Personalized neoantigen cancer vaccine plus anti-PD-1 therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline immune features analysis
Number of subjects: 21
Study: 33294860

Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade
Number of subjects: 0
Study: 33294861

Group type: EXPERIMENTAL
Intervention: Tocilizumab (monoclonal anti-IL-6 receptor) treatment
Number of subjects: 0
Study: 33294918

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study: 33295204

Group type: EXPERIMENTAL
Intervention: Weight Management Program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonintervention
Number of subjects: 20
Study: 33295277

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) therapy
Number of subjects: 126
Study: 33295643

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 12127
Study: 33295823

Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy (NHFT) with heated humidified air (flow: 40 L/min with 80% oxygen) during breath-hold (BH) training and treatment.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nasal high-flow therapy (NHFT) during breath-hold (BH) training and treatment.
Number of subjects: 10
Study: 33296036

Group type: EXPERIMENTAL
Intervention: LBW group (0.63 gI/kg of LBW)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: LBW group
Number of subjects: 274

Group type: COMPARATOR
Intervention: TBW group
Number of subjects: 274
Study: 33296042

Group type: EXPERIMENTAL
Intervention: ORM-12741
Number of subjects: 0
Study: 33296127

Group type: EXPERIMENTAL
Intervention: 1 kHz spinal cord stimulation
Number of subjects: 0
Study: 33296242

Group type: EXPERIMENTAL
Intervention: Melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 157
Study: 33296533

Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT) performed in 254 patients (DT+ group)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No Defibrillation Testing (DT) in 166 patients (DT- group)
Number of subjects: 420
Study: 33296696

Group type: EXPERIMENTAL
Intervention: Right anterior insula
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Right ventral-posterior insula
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Right ventral-posterior insular structural covariance
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Whole-brain SBNs (salience network, default mode network, central executive network)
Number of subjects: 157
Study: 33296830

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P/G)
Number of subjects: 299
Study: 33296868

Group type: EXPERIMENTAL
Intervention: Web-based survey during COVID-19 confinement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second web-based survey 1 year after lockdown
Number of subjects: 0
Study: 33297779

Group type: EXPERIMENTAL
Intervention: Various biomarkers (genetic, plasmatic, cellular, microbiome-related) studied for GVHD diagnosis and prognosis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment tailored to patients' needs based on biomarker identification.
Number of subjects: 0
Study: 33297794

Group type: EXPERIMENTAL
Intervention: idelalisib
Number of subjects: 0
Study: 33297800

Group type: EXPERIMENTAL
Intervention: Modular neck stems
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard neck stems
Number of subjects: 75
Study: 33297819

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33297992

Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF; healthy school lunch and structured physical activity)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF)
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Physical Activity School (PAS; structured physical activity)
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Control schools (regular Dutch curriculum)
Number of subjects: 1676
Study: 33298010

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 245
Study: 33298159

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET), up to six sessions with partial telehealth delivery
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 8
Study: 33298471

Group type: EXPERIMENTAL
Intervention: Precarious circumstances with situational facilitators
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Precarious circumstances without situational facilitators
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Marginalisation
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Clinical presentation
Number of subjects: 2066
Study: 33298619

Group type: EXPERIMENTAL
Intervention: Nivolumab combined with bempegaldesleukin (BEMPEG, NKTR-214)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 1

Group type: COMPARATOR
Intervention: bempegaldesleukin (BEMPEG, NKTR-214)
Number of subjects: 1
Study: 33299539

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) measuring mean flow velocities (MFVs) of cerebral arteries
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acute hydrocephalus and delayed cerebral ischemia (DCI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increased mean flow velocities (MFV)
Number of subjects: 40
Study: 33300144

Group type: EXPERIMENTAL
Intervention: African-ancestry weighted genetic risk score (AFR wGRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: European-ancestry weighted genetic risk score (EUR wGRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-ancestry weighted genetic risk score
Number of subjects: 0

Group type: COMPARATOR
Intervention: AFR wGRS
Number of subjects: 0
Study: 33300151

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMB) in DLB patients
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMB) in AD patients
Number of subjects: 158

Group type: COMPARATOR
Intervention: Cerebral microbleeds (CMB) in DLB patients with and without CMB
Number of subjects: 158
Study: 33300372

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 0
Study: 33300403

Group type: EXPERIMENTAL
Intervention: Hormone-sensitive prostate cancer (HSPC)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Metastatic hormone-sensitive prostate cancer (mHSPC)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Non-metastatic castration-resistant prostate cancer (nmCRPC)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Metastatic castration-resistant prostate cancer (mCRPC)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization (HRU) costs
Number of subjects: 1869
Study: 33300564

Group type: EXPERIMENTAL
Intervention: Two-site anorectal and pharyngeal testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-site (anorectum and urethra/cervix) testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-site testing
Number of subjects: 0
Study: 33301080

Group type: EXPERIMENTAL
Intervention: Clinical model for sudden death (SD)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Clinical model for pump failure death (PFD)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Inclusion of NT-proBNP in the SD model
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Inclusion of ECG and biochemical parameters
Number of subjects: 4116
Study: 33301227

Group type: EXPERIMENTAL
Intervention: Avapritinib 300 mg once daily
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Avapritinib with dose modification
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Avapritinib without dose modification
Number of subjects: 250
Study: 33301375

Group type: EXPERIMENTAL
Intervention: MP0250 (8 mg/kg, once every 2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MP0250 (12 mg/kg, once every 2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MP0250 (various doses)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MP0250
Number of subjects: 45
Study: 33301630

Group type: EXPERIMENTAL
Intervention: Early treatment (initiated within the first seven days after birth)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Very early treatment (initiated within the first 72 hours after birth)
Number of subjects: 910
Study: 33301930

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 33302031

Group type: EXPERIMENTAL
Intervention: Idasanutlin monotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Idasanutlin in combination with cytarabine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Idasanutlin (MBP formulation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Idasanutlin (SDP formulation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 122

Group type: COMPARATOR
Intervention: Early death rate
Number of subjects: 122
Study: 33302114

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors
Number of subjects: 94
Study: 33302225

Group type: EXPERIMENTAL
Intervention: ADHD with EEG changes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ADHD with epilepsy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ADHD without EEG changes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epilepsy
Number of subjects: 100
Study: 33302264

Group type: EXPERIMENTAL
Intervention: Oxygen-18 and carbon-13 isotopes in eCO
Number of subjects: 0
Study: 33302891

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside >1000 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Iron isomaltoside ≤1000 mg
Number of subjects: 256
Study: 33303023

Group type: EXPERIMENTAL
Intervention: Resistant potato starch (RPS; MSPrebiotic®, N = 38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (N = 37)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resistant potato starch (RPS; MSPrebiotic®)
Number of subjects: 75
Study: 33303117

Group type: EXPERIMENTAL
Intervention: Percutaneous edge-to-edge mitral valve repair (PMVR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Staged PMVR
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Transcatheter interventions
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 106
Study: 33303435

Group type: EXPERIMENTAL
Intervention: CCTA and FFR based surgical revascularisation
Number of subjects: 0
Study: 33303463

Group type: EXPERIMENTAL
Intervention: Adapted Chinese version of UCLA 3-item Loneliness Scale
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Loneliness score of 3
Number of subjects: 1653
Study: 33303471

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship programme (ASP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection on antimicrobial use and susceptibility of organisms
Number of subjects: 0
Study: 33303470

Group type: EXPERIMENTAL
Intervention: Confinement group
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Epidemic group
Number of subjects: 927

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: All groups (Confinement, Epidemic, Control)
Number of subjects: 927
Study: 33303537

Group type: EXPERIMENTAL
Intervention: Free-breathing MRI
Number of subjects: 0
Study: 33303539

Group type: EXPERIMENTAL
Intervention: COVID-19 recovery evaluation at 100 days
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Lung function analysis
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sequential follow-up evaluations at 60 and 100 days
Number of subjects: 145
Study: 33303555

Group type: EXPERIMENTAL
Intervention: Blood eosinophil count of ≥300 cells·µL
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1120